List of Contributors |
|
xvi | |
Preface |
|
xx | |
List of Abbreviations |
|
xxii | |
Part I: Current Sample Preparation Techniques in LC-MS Bioanalysis |
|
1 | (200) |
|
1 Basic Sample Preparation Techniques in LC-MS Bioanalysis: Protein Precipitation, Liquid-Liquid Extraction, and Solid-Phase Extraction |
|
|
3 | (28) |
|
|
|
|
|
3 | (1) |
|
1.2 Physicochemical Properties of Drugs and Their Metabolites |
|
|
4 | (1) |
|
1.2.1 Hydrophilicity vs. Lipophilicity of Analyte(s) |
|
|
4 | (1) |
|
1.2.2 Protolytic Properties of Analyte(s) |
|
|
4 | (1) |
|
1.3 Pre-analytical Variables of Analyte(s) of Interest in Biological Matrix |
|
|
5 | (2) |
|
|
5 | (1) |
|
1.3.2 Nonspecific Binding |
|
|
6 | (1) |
|
|
6 | (1) |
|
1.3.4 Blood-to-plasma Ratio and Red Blood Cell Partition |
|
|
6 | (1) |
|
1.4 Most Commonly Used Sample Preparation Methods in LC-MS Bioanalysis |
|
|
7 | (20) |
|
1.4.1 Protein Precipitation (PPT) |
|
|
7 | (1) |
|
1.4.1.1 Water-miscible Organic Solvents |
|
|
7 | (1) |
|
|
8 | (3) |
|
1.4.2 Liquid-Liquid Extraction (LLE) |
|
|
11 | (1) |
|
1.4.2.1 Mechanism of LLE and Extraction Recovery |
|
|
11 | (1) |
|
|
13 | (1) |
|
1.4.2.3 General Procedures in LLE |
|
|
14 | (1) |
|
1.4.2.4 Application of LLE in LC-MS Bioanalysis |
|
|
15 | (1) |
|
1.4.2.5 Other Formats of LLE |
|
|
17 | (1) |
|
1.4.3 Solid-phase Extraction (SPE) |
|
|
18 | (1) |
|
1.4.3.1 SPE Stationary Phases (Sorbents) |
|
|
18 | (1) |
|
1.4.3.2 Common SPE Platforms in LC-MS Bioanalysis |
|
|
19 | (1) |
|
1.4.3.3 General SPE Workflows |
|
|
20 | (1) |
|
1.4.3.4 Other Formats of SPE |
|
|
26 | (1) |
|
1.4.4 Combination of PPT, LLE, and/or SPE in LC-MS Bioanalysis |
|
|
26 | (1) |
|
1.4.4.1 Combination of PPT and LLE |
|
|
26 | (1) |
|
1.4.4.2 Combination of PPT and SPE |
|
|
26 | (1) |
|
1.4.4.3 Combination of LLE and SPE |
|
|
26 | (1) |
|
|
27 | (1) |
|
|
27 | (4) |
|
2 Online Extraction and Column Switching Techniques in LC-MS Bioanalysis |
|
|
31 | (14) |
|
|
|
|
31 | (1) |
|
|
32 | (1) |
|
2.2.1 Single-column System |
|
|
32 | (1) |
|
|
32 | (1) |
|
2.2.3 Staggered Parallel Online Extraction Systems |
|
|
32 | (1) |
|
2.3 Commonly Used Online Extraction Techniques |
|
|
33 | (7) |
|
2.3.1 Turbulent/High Flow Chromatography |
|
|
33 | (2) |
|
2.3.2 Restricted Access Media |
|
|
35 | (1) |
|
2.3.3 Monolithic Materials |
|
|
35 | (1) |
|
2.3.4 Hydrophilic Interaction Liquid Chromatography |
|
|
36 | (1) |
|
2.3.5 Immunoaffinity Extraction |
|
|
37 | (1) |
|
2.3.6 Disposable Extraction Cartridges-Online SPE |
|
|
38 | (1) |
|
2.3.7 Online Extraction of Dried Blood Spot (DBS) Samples |
|
|
38 | (1) |
|
|
39 | (1) |
|
2.4 Considerations for Utilizing Online Extraction Techniques |
|
|
40 | (1) |
|
2.4.1 Advantages and Limitations |
|
|
40 | (1) |
|
2.4.2 Strategies for Online Extraction Method Development |
|
|
40 | (1) |
|
|
41 | (1) |
|
|
42 | (3) |
|
3 Equilibrium Dialysis, Ultracentrifugation, and Ultrafiltration in LC-MS Bioanalysis |
|
|
45 | (7) |
|
|
|
|
45 | (1) |
|
3.2 Challenges and Considerations |
|
|
46 | (1) |
|
3.3 Experimental Procedures |
|
|
46 | (3) |
|
3.3.1 Equilibrium Dialysis |
|
|
47 | (1) |
|
|
48 | (1) |
|
3.3.3 Ultracentrifugation |
|
|
49 | (1) |
|
|
49 | (2) |
|
|
51 | (1) |
|
4 Phospholipid Depletion Techniques in LC-MS Bioanalysis |
|
|
52 | (16) |
|
|
|
|
52 | (1) |
|
4.2 Impact of Phospholipids on Bioanalytical Methods |
|
|
52 | (3) |
|
4.3 Investigating Matrix Effects Associated with Phospholipids |
|
|
55 | (1) |
|
4.4 Minimizing Matrix Effects Associated with Phospholipids |
|
|
56 | (1) |
|
|
56 | (1) |
|
4.4.2 Column Manipulations |
|
|
56 | (1) |
|
|
56 | (1) |
|
|
56 | (1) |
|
4.4.5 Other Experimental Modifications |
|
|
57 | (1) |
|
4.5 Removing Phospholipids Prior to LC-MS Analysis |
|
|
57 | (3) |
|
4.5.1 Protein Precipitations |
|
|
57 | (1) |
|
4.5.2 Liquid-Liquid Extraction and Supported Liquid Membranes |
|
|
57 | (1) |
|
4.5.3 Supported Liquid Extraction |
|
|
58 | (1) |
|
4.5.4 Electrostatic Removal |
|
|
58 | (1) |
|
4.5.5 Solid-Phase Extraction |
|
|
58 | (2) |
|
4.6 Example Methods that Demonstrate Successful Phospholipid Removal |
|
|
60 | (3) |
|
|
63 | (1) |
|
|
64 | (1) |
|
|
64 | (4) |
|
5 Salting-out Assisted Liquid-Liquid Extraction (SALLE) in LC-MS Bioanalysis |
|
|
68 | (8) |
|
|
|
|
68 | (1) |
|
5.2 Considerations in Developing a SALLE Method |
|
|
68 | (4) |
|
|
68 | (3) |
|
5.2.2 Water-Miscible Solvent |
|
|
71 | (1) |
|
|
71 | (1) |
|
5.3 Combination of SALLE with Other Extraction Techniques |
|
|
72 | (1) |
|
5.4 Matrix Effect in SALLE |
|
|
72 | (1) |
|
5.5 Miniaturization and Automatization |
|
|
73 | (1) |
|
|
73 | (1) |
|
|
73 | (3) |
|
6 Supported Liquid Extraction (SLE) in LC-MS Bioanalysis |
|
|
76 | (9) |
|
|
|
|
76 | (1) |
|
|
76 | (1) |
|
6.3 Advantages and Limitation of SLE in Quantitative LC-MS Bioanalysis |
|
|
77 | (2) |
|
|
77 | (1) |
|
|
78 | (1) |
|
6.4 Key Consideration in Developing Robust SLE-LC-MS Bioanalytical Method |
|
|
79 | (1) |
|
6.5 Representative Protocols |
|
|
80 | (1) |
|
6.5.1 Material, Supplies, and Equipment |
|
|
80 | (1) |
|
6.5.2 Protocols for SLE Cartridge and Plate Processing |
|
|
80 | (1) |
|
|
81 | (1) |
|
|
82 | (3) |
|
7 Immunocapture in LC-MS Bioanalysis |
|
|
85 | (13) |
|
|
|
85 | (1) |
|
7.2 Experimental Workflow and Optimization |
|
|
85 | (1) |
|
7.3 Considerations on the Selection of Capture Reagents and the Limitations |
|
|
86 | (3) |
|
7.4 Platforms for Immunocapture |
|
|
89 | (1) |
|
7.5 Internal Standard Selection |
|
|
89 | (1) |
|
7.6 Performance Evaluation |
|
|
90 | (1) |
|
7.7 Applications and Representative Protocols |
|
|
91 | (3) |
|
7.7.1 Endogenous Peptides/Proteins |
|
|
91 | (1) |
|
7.7.2 Protein-based Biotherapeutics |
|
|
92 | (1) |
|
|
93 | (1) |
|
7.8 Validation Criteria and Regulatory Considerations |
|
|
94 | (1) |
|
|
95 | (1) |
|
|
95 | (3) |
|
8 Microextraction Techniques in LC-MS Bioanalysis |
|
|
98 | (19) |
|
|
|
|
|
|
98 | (1) |
|
8.2 Solid-Phase Microextraction |
|
|
99 | (9) |
|
8.2.1 Conventional Fiber SPME |
|
|
99 | (3) |
|
8.2.2 Stir-Bar Sorptive Extraction |
|
|
102 | (1) |
|
8.2.3 Thin-Film Microextraction |
|
|
102 | (1) |
|
|
102 | (1) |
|
|
103 | (1) |
|
8.2.5.1 Solid-Phase Dynamic Extraction |
|
|
103 | (1) |
|
8.2.5.2 Microextraction by Packed Sorbent |
|
|
103 | (1) |
|
8.2.5.3 Fiber-Packed Needle Microextraction |
|
|
107 | (1) |
|
|
107 | (1) |
|
8.2.7 New Sorbents for SPME |
|
|
107 | (1) |
|
8.2.7.1 Monolithic Sorbent |
|
|
107 | (1) |
|
|
108 | (1) |
|
8.3 Liquid-Phase Microextraction |
|
|
108 | (5) |
|
8.3.1 Single-Drop Microextraction |
|
|
108 | (2) |
|
8.3.2 Hollow Fiber Liquid-Phase Microextraction |
|
|
110 | (1) |
|
8.3.3 Dispersive Liquid-Liquid Microextraction |
|
|
110 | (1) |
|
8.3.4 Influence Factors on LPME Efficiency |
|
|
111 | (2) |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
113 | (4) |
|
9 Microsampling Applications with LC-MS Bioanalysis |
|
|
117 | (11) |
|
|
|
|
117 | (1) |
|
9.2 Plasma Microsampling Considerations |
|
|
118 | (3) |
|
|
118 | (1) |
|
9.2.2 Interaction with Thixotropic Gel |
|
|
118 | (2) |
|
9.2.3 Sample Manipulation |
|
|
120 | (1) |
|
9.2.4 Extraction, LC-MS/MS Analysis, and Detection |
|
|
120 | (1) |
|
9.3 Dried Blood (Matrix) Spot (DBS) Considerations |
|
|
121 | (2) |
|
|
121 | (1) |
|
9.3.2 Sample Manipulation |
|
|
122 | (1) |
|
9.3.3 Extraction, LC-MS/MS Analysis, and Detection |
|
|
123 | (1) |
|
9.4 Volumetric Absorptive Microsampling (VAMS) |
|
|
123 | (2) |
|
|
123 | (1) |
|
9.4.2 Sample Manipulation |
|
|
124 | (1) |
|
9.4.3 Extraction, LC-MS/MS Analysis, and Detection |
|
|
124 | (1) |
|
|
125 | (1) |
|
|
126 | (1) |
|
|
126 | (1) |
|
|
126 | (2) |
|
10 Nanomaterials for Sample Preparation in LC-MS Bioanalysis |
|
|
128 | (11) |
|
Rodrigo A. Gonzalez-Fuenzalida |
|
|
|
|
|
|
128 | (1) |
|
10.2 Carbon Nanomaterials |
|
|
128 | (5) |
|
|
133 | (3) |
|
10.3.1 Metal Nanoparticles |
|
|
133 | (1) |
|
10.3.2 Metal Oxide Nanoparticles |
|
|
134 | (1) |
|
10.4 Nanoporous Materials |
|
|
135 | (1) |
|
10.4.1 Polymeric Nanomaterials |
|
|
135 | (1) |
|
10.4.2 Mesoporous Materials |
|
|
135 | (1) |
|
10.4.3 Molecular Imprinted Polymers (MIPs) |
|
|
136 | (1) |
|
|
136 | (1) |
|
|
136 | (1) |
|
|
137 | (2) |
|
11 Sample Preparation via Molecularly Imprinted Polymers (MIPs) in LC-MS Bioanalysis |
|
|
139 | (13) |
|
|
|
|
139 | (1) |
|
|
139 | (3) |
|
11.2.1 Template and Monomer(s) |
|
|
140 | (1) |
|
|
141 | (1) |
|
|
141 | (1) |
|
11.3 MIPs for Sample Preparation in Bioanalysis |
|
|
142 | (1) |
|
11.3.1 Molecularly Imprinted Solid-phase Extraction (MISPE) |
|
|
142 | (1) |
|
11.3.1.1 Off-line Protocols |
|
|
142 | (2) |
|
11.3.1.2 Online Protocols |
|
|
144 | (1) |
|
11.3.1.3 In-line Protocols |
|
|
145 | (1) |
|
|
146 | (1) |
|
11.3.2 MIPs in Other Sample Preparation Techniques |
|
|
146 | (1) |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
147 | (5) |
|
12 Stir-bar Sorptive Extraction for Sample Preparation in LC-MS Bioanalysis |
|
|
152 | (11) |
|
|
|
|
|
152 | (1) |
|
|
153 | (1) |
|
|
154 | (1) |
|
12.3.1 Extraction Procedure |
|
|
154 | (1) |
|
|
154 | (1) |
|
12.3.2.1 Thermal Desorption |
|
|
154 | (1) |
|
12.3.2.2 Liquid Desorption |
|
|
155 | (1) |
|
|
155 | (1) |
|
12.4.1 In Situ Derivatization |
|
|
155 | (1) |
|
12.4.2 On-Stir-Bar Derivatization |
|
|
155 | (1) |
|
12.4.3 Post-Extraction Mode |
|
|
156 | (1) |
|
|
156 | (2) |
|
|
158 | (3) |
|
|
161 | (1) |
|
|
161 | (2) |
|
13 Monolithic Spin Column Extraction in LC-MS Bioanalysis |
|
|
163 | (11) |
|
|
|
|
163 | (1) |
|
13.2 History of Monoliths |
|
|
163 | (1) |
|
13.3 The Use of Monolith as Sorbent in Solid-Phase Extraction |
|
|
164 | (1) |
|
13.4 Monolithic Spin Column for Sample Preparation |
|
|
165 | (6) |
|
13.4.1 Extraction Procedure |
|
|
165 | (1) |
|
13.4.2 Extraction Mechanism |
|
|
165 | (2) |
|
13.4.3 Advantages and Limitations |
|
|
167 | (1) |
|
13.4.3.1 Zero Dead Volume |
|
|
167 | (1) |
|
|
167 | (1) |
|
13.4.3.3 Ease of Operation |
|
|
167 | (1) |
|
13.4.3.4 Ease of Shape Modification |
|
|
167 | (1) |
|
13.4.3.5 Loading Sample Volume |
|
|
167 | (1) |
|
13.4.3.6 High Viscosity Sample |
|
|
168 | (1) |
|
13.4.3.7 Commercial Suppliers |
|
|
168 | (1) |
|
|
168 | (3) |
|
|
171 | (3) |
|
14 Aptamer-based Sample Preparation in LC-MS Bioanalysis |
|
|
174 | (14) |
|
|
|
|
|
|
174 | (1) |
|
14.2 Aptamer-based Sample Preparation |
|
|
175 | (6) |
|
14.2.1 Aptamer-based Solid-phase Extraction |
|
|
175 | (1) |
|
14.2.1.1 Aptamer-based Affinity Columns for SPE |
|
|
175 | (1) |
|
14.2.1.2 Aptamer-based Magnetic SPE |
|
|
175 | (1) |
|
14.2.1.3 Aptamer-based Surface Affinity SPE |
|
|
178 | (1) |
|
14.2.1.4 Aptamer-functionalized Materials for Other SPE Format |
|
|
178 | (3) |
|
14.2.2 Aptamer-based Solid-phase Microextraction |
|
|
181 | (1) |
|
14.2.3 Aptamer-based Microfluidic Sample Preparation |
|
|
181 | (1) |
|
14.3 Representative Protocols |
|
|
181 | (4) |
|
|
185 | (1) |
|
|
185 | (1) |
|
|
185 | (3) |
|
15 Sample Extraction via Electromembrane in LC-MS Bioanalysis |
|
|
188 | (13) |
|
|
|
|
|
188 | (2) |
|
15.2 Factors Affecting the Extraction Efficiency of EME |
|
|
190 | (1) |
|
15.2.1 Composition of Supported Liquid Membrane and Nature of the Supports |
|
|
190 | (1) |
|
15.2.2 Composition of Acceptor and Donor (Sample) Phase |
|
|
190 | (1) |
|
15.2.2.1 For Extraction of Basic Drugs |
|
|
190 | (1) |
|
15.2.2.2 For Extraction of Acidic Drugs |
|
|
190 | (1) |
|
15.2.3 Electrical Field Application: Voltage and Time |
|
|
191 | (1) |
|
15.2.4 Agitation/Stirring Speed |
|
|
191 | (1) |
|
15.2.5 Presence of Salt/Salt Effect |
|
|
191 | (1) |
|
|
191 | (1) |
|
15.3 Recent Developments in EME |
|
|
191 | (2) |
|
|
191 | (1) |
|
|
192 | (1) |
|
|
192 | (1) |
|
|
192 | (1) |
|
15.3.5 EME Combined with Other Preparation Techniques |
|
|
193 | (1) |
|
15.4 Bioanalytical Applications |
|
|
193 | (4) |
|
|
193 | (3) |
|
15.4.2 Biomolecule Analysis |
|
|
196 | (1) |
|
|
197 | (1) |
|
|
197 | (4) |
Part II: Matrix-specific Sample Preparation Techniques in LC-MS Bioanalysis |
|
201 | (48) |
|
16 Tissue Sample Preparation in LC-MS Bioanalysis |
|
|
203 | (14) |
|
|
|
|
203 | (1) |
|
16.2 Selection of Homogenization Method |
|
|
203 | (6) |
|
|
203 | (1) |
|
16.2.2 Homogenization Techniques |
|
|
204 | (1) |
|
16.2.2.1 Rotor-Stator Homogenization |
|
|
204 | (1) |
|
|
206 | (1) |
|
16.2.2.3 Ultrasonic Tissue Disruption |
|
|
208 | (1) |
|
16.2.2.4 Chemical Digestion |
|
|
208 | (1) |
|
16.2.2.5 Enzymatic Digestion |
|
|
208 | (1) |
|
|
209 | (1) |
|
|
209 | (1) |
|
16.3.2 For Fibrous (Tough) Tissue |
|
|
209 | (1) |
|
|
209 | (1) |
|
16.4 Protocols for Special Tissue Sample Preparation |
|
|
210 | (2) |
|
|
210 | (1) |
|
|
210 | (1) |
|
|
211 | (1) |
|
|
211 | (1) |
|
16.5 Challenges Associated with Tissue Homogenization |
|
|
212 | (2) |
|
|
212 | (1) |
|
16.5.2 Homogenization of Tissue for the Analysis of Labile Analyte |
|
|
212 | (1) |
|
|
212 | (1) |
|
|
212 | (1) |
|
16.5.5 Analyte Extraction |
|
|
212 | (2) |
|
|
214 | (1) |
|
|
214 | (3) |
|
17 Sample Preparation for LC-MS Bioanalysis of Peripheral Blood Mononuclear Cells |
|
|
217 | (8) |
|
|
|
|
217 | (1) |
|
17.2 Peripheral Blood Mononuclear Cells (PBMCs) |
|
|
217 | (1) |
|
17.3 Sample Preparation Workflow for LC-MS Bioanalysis of PBMC Samples |
|
|
217 | (3) |
|
|
217 | (1) |
|
17.3.1.1 Ficoll®/Histopaque® Method |
|
|
218 | (1) |
|
17.3.1.2 Cell Preparation Tube (CPT) Method |
|
|
218 | (1) |
|
17.3.1.3 Factors That Need to Be Considered in Cell Separation |
|
|
219 | (1) |
|
17.3.2 Cell Counting and Recovery |
|
|
219 | (1) |
|
17.3.3 Cellular Volume for Concentration Conversion |
|
|
220 | (1) |
|
17.3.4 Cell Lysis and Extraction |
|
|
220 | (1) |
|
17.4 Representative Protocols |
|
|
220 | (2) |
|
17.4.1 Ficoll®-Paque® Plus Density Gradient Separation Method |
|
|
220 | (1) |
|
|
221 | (1) |
|
17.4.3 Additional Consideration in LC-MS Bioanalysis for PBMC Samples |
|
|
221 | (1) |
|
|
221 | (1) |
|
|
222 | (1) |
|
|
222 | (1) |
|
|
222 | (3) |
|
18 Sample Preparation for LC-MS Bioanalysis of Urine, Cerebrospinal Fluid, Synovial Fluid, Sweat, Tears, and Aqueous Humor Samples |
|
|
225 | (13) |
|
|
|
225 | (1) |
|
18.2 Sample Preparation Methods for Urine |
|
|
225 | (5) |
|
18.2.1 Direct Dilution for Urine Samples |
|
|
225 | (1) |
|
18.2.2 Liquid-Liquid Extraction for Urine Samples |
|
|
226 | (1) |
|
18.2.3 Solid-Phase Extraction for Urine Samples |
|
|
226 | (4) |
|
18.3 Sample Preparation Methods for Cerebrospinal Fluid |
|
|
230 | (1) |
|
18.4 Sample Preparation Methods for Synovial Fluid |
|
|
231 | (1) |
|
18.5 Sample Preparation Methods for Sweat |
|
|
231 | (3) |
|
18.6 Sample Preparation Methods for Tears |
|
|
234 | (2) |
|
18.7 Sample Preparation Methods for Aqueous Humor |
|
|
236 | (1) |
|
|
236 | (1) |
|
|
236 | (2) |
|
19 Sample Preparation for LC-MS Bioanalysis of Liposomal Samples |
|
|
238 | (11) |
|
Wenying Jian, Rao N.V.S. Mamidi, Naidong Weng |
|
|
|
238 | (1) |
|
19.2 Major Types of Sample Extraction Techniques for Liposomal Samples |
|
|
239 | (3) |
|
19.2.1 Solid-Phase Extraction |
|
|
239 | (2) |
|
|
241 | (1) |
|
19.2.3 Ultracentrifugation |
|
|
241 | (1) |
|
|
242 | (1) |
|
19.3 Key Considerations in Sample Preparation for Liposomal Samples |
|
|
242 | (3) |
|
|
242 | (1) |
|
|
243 | (1) |
|
19.3.3 Quality Control Samples |
|
|
243 | (1) |
|
|
244 | (1) |
|
19.3.5 Addition of Internal Standard |
|
|
244 | (1) |
|
|
245 | (1) |
|
19.4.1 SPE Procedure for Measurement of Nonencapsulated and Encapsulated Analyte in Liposomal Samples |
|
|
245 | (1) |
|
19.4.2 Ultrafiltration Procedure for Measurement of Nonencapsulated Analyte in Liposomal Samples |
|
|
245 | (1) |
|
19.4.3 Protein Precipitation Procedure for Measurement of Total Analyte in Liposomal Samples |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
246 | (3) |
Part III: Sample Preparation Techniques for LC-MS Bioanalysis of Challenging Molecules |
|
249 | (102) |
|
20 Key Pre-analytical Considerations in LC-MS Bioanalysis |
|
|
251 | (9) |
|
Fumin Li, B®uce J. Hidy, Rand G. Jenkins |
|
|
|
251 | (1) |
|
20.2 The Pre-analytical Phase |
|
|
251 | (2) |
|
20.3 Bioanalytical Evaluation-planning |
|
|
253 | (2) |
|
20.3.1 Study-related Considerations |
|
|
253 | (1) |
|
20.3.1.1 Study Type and Development Phase |
|
|
253 | (1) |
|
20.3.1.2 Study Subject Population |
|
|
253 | (1) |
|
20.3.1.3 Drug and Administration |
|
|
254 | (1) |
|
20.3.1.4 Samples to Be Collected for Analysis |
|
|
254 | (1) |
|
20.3.1.5 Analyte(s) to Be Measured |
|
|
254 | (1) |
|
|
254 | (1) |
|
20.3.2 Assay-related Considerations |
|
|
254 | (1) |
|
20.3.2.1 Analyte(s) and Properties-Small vs. Large Molecule |
|
|
254 | (1) |
|
20.3.2.2 Matrix and Species |
|
|
255 | (1) |
|
20.4 Common Pre-analytical Issues in LC-MS Bioanalysis |
|
|
255 | (3) |
|
20.4.1 Stability in Matrix |
|
|
255 | (2) |
|
20.4.2 Nonspecific Binding |
|
|
257 | (1) |
|
|
258 | (1) |
|
|
259 | (1) |
|
21 Derivatization in Sample Preparation for LC-MS Bioanalysis |
|
|
260 | (15) |
|
|
|
|
260 | (1) |
|
21.2 Derivatization Strategies |
|
|
260 | (4) |
|
21.3 Key Considerations for Derivatization |
|
|
264 | (1) |
|
21.4 Application of Derivatization for Quantitative LC-MS Bioanalysis |
|
|
265 | (5) |
|
21.4.1 Derivatization for Quantitative LC-MS Bioanalysis of Prasugrel |
|
|
266 | (1) |
|
21.4.1.1 Stability of Prasugrel Derivative |
|
|
266 | (1) |
|
21.4.1.2 Step-by-step Procedure of Derivatization |
|
|
266 | (1) |
|
21.4.1.3 LC-MS Behavior of Prasugrel Derivative |
|
|
267 | (1) |
|
21.4.2 Derivatization for Quantitative LC-MS Bioanalysis of Minodronic Acid |
|
|
268 | (1) |
|
21.4.2.1 Step-by-step Procedure of Derivatization |
|
|
268 | (1) |
|
21.4.2.2 LC-MS Behavior of MA Derivative |
|
|
268 | (1) |
|
21.4.2.3 Key Consideration for MA Derivatization |
|
|
269 | (1) |
|
21.4.3 Derivatization for Quanti tative LC-MS Bioanalysis of α-Fluoro-β-alanine, 5-Fluorouracil, and Capecitabine |
|
|
269 | (1) |
|
21.4.3.1 Step-by-step Procedure of Derivatization |
|
|
270 | (1) |
|
21.4.3.2 LC-MS Behavior of DNS-Cl Derivatives |
|
|
270 | (1) |
|
|
270 | (1) |
|
|
271 | (4) |
|
22 Sample Preparation for LC-MS Bioanalysis of Lipids |
|
|
275 | (9) |
|
|
|
|
|
|
275 | (1) |
|
22.2 Sample Preparation for LC-MS Bioanalysis of Lipids |
|
|
275 | (5) |
|
22.2.1 LC-MS Bioanalysis of Lipids |
|
|
275 | (2) |
|
22.2.2 Sample Preparation for LC-MS Bioanalysis of Lipids |
|
|
277 | (1) |
|
22.2.2.1 Key Considerations for LC-MS Bioanalysis of Lipids |
|
|
277 | (1) |
|
22.2.2.2 Common Sample Preparation Methods for Lipids |
|
|
277 | (1) |
|
|
278 | (1) |
|
22.2.3 Typical Protocols of Sample Extraction for Lipid LC-MS Bioanalysis |
|
|
279 | (1) |
|
22.2.3.1 A Typical Protocol of Folch LLE |
|
|
279 | (1) |
|
22.2.3.2 A Typical Protocol of LLE |
|
|
279 | (1) |
|
22.2.3.3 A Typical Protocol of SPE |
|
|
280 | (1) |
|
22.2.3.4 A Typical Protocol of LLE with Derivatization |
|
|
280 | (1) |
|
22.3 Case Studies of LC-MS Bioanalysis of Lipids |
|
|
280 | (1) |
|
22.3.1 Targeted LC-MS/MS Analysis of Lipid Metabolites Involved in Inflammation |
|
|
280 | (1) |
|
22.3.2 LC-ECAPCl/MS Analysis of Bioactive Eicosanoid Lipids |
|
|
281 | (1) |
|
|
281 | (1) |
|
|
282 | (2) |
|
23 Sample Preparation for LC-MS Bioanalysis of Peptides |
|
|
284 | (20) |
|
|
|
284 | (1) |
|
23.2 Properties of Peptides and Sample Pretreatment |
|
|
285 | (2) |
|
|
286 | (1) |
|
|
286 | (1) |
|
23.3 Sample Preparation Strategies |
|
|
287 | (9) |
|
23.3.1 Protein Precipitation |
|
|
287 | (1) |
|
23.3.1.1 Overview of Protein Precipitation |
|
|
287 | (1) |
|
23.3.1.2 PPT in Peptide Bioanalysis |
|
|
287 | (1) |
|
23.3.1.3 A Representative PPT Protocol |
|
|
288 | (1) |
|
23.3.2 Liquid-Liquid Extraction |
|
|
288 | (1) |
|
|
288 | (1) |
|
23.3.2.2 LLE in Peptide Bioanalysis |
|
|
288 | (1) |
|
23.3.2.3 A Representative LLE Protocol |
|
|
289 | (1) |
|
23.3.2.4 Salting-out Assisted LLE |
|
|
289 | (1) |
|
23.3.2.5 A Representative SALLE Protocol |
|
|
290 | (1) |
|
23.3.3 Solid-Phase Extraction |
|
|
290 | (1) |
|
|
290 | (1) |
|
23.3.3.2 SPE in Peptide Bioanalysis |
|
|
290 | (1) |
|
23.3.3.3 A Representative SPE Protocol |
|
|
291 | (1) |
|
|
291 | (1) |
|
23.3.4 Immunoaffinity Extraction |
|
|
292 | (1) |
|
23.3.4.1 Overview of Immunoaffinity Extraction |
|
|
292 | (1) |
|
23.3.4.2 IAE in Peptide Bioanalysis |
|
|
292 | (1) |
|
23.3.4.3 A Representative IAE Protocol |
|
|
294 | (1) |
|
23.3.5 Other Sample Preparation Techniques for Peptides |
|
|
294 | (1) |
|
23.3.5.1 Immobilized Metal Ion Affinity Chromatography |
|
|
294 | (1) |
|
23.3.5.2 Molecularly Imprinted Polymers |
|
|
295 | (1) |
|
|
295 | (1) |
|
|
295 | (1) |
|
|
296 | (1) |
|
|
296 | (1) |
|
|
297 | (1) |
|
|
297 | (7) |
|
24 Sample Preparation for LC-MS Bioanalysis of Proteins |
|
|
304 | (15) |
|
|
|
304 | (1) |
|
24.2 Intact Versus Digested Protein Analysis |
|
|
305 | (1) |
|
|
306 | (2) |
|
|
308 | (1) |
|
24.5 Protein Extraction (Before Digestion) |
|
|
308 | (4) |
|
24.5.1 Differential Protein Precipitation |
|
|
308 | (1) |
|
|
309 | (2) |
|
24.5.3 Antibody-free Extraction |
|
|
311 | (1) |
|
24.6 Peptide Extraction (After Digestion) |
|
|
312 | (2) |
|
|
312 | (1) |
|
24.6.2 Antibody-Free Extraction |
|
|
313 | (1) |
|
24.7 Combined Protein and Peptide Extraction |
|
|
314 | (1) |
|
|
314 | (1) |
|
|
315 | (4) |
|
25 Sample Preparation for LC-MS Bioanalysis of Oligonucleotides |
|
|
319 | (16) |
|
|
|
|
|
|
319 | (1) |
|
25.2 Properties of Oligonucleotides and Associated Challenges in LC-MS Bioanalysis |
|
|
319 | (3) |
|
25.3 Classes of Oligonucleotides |
|
|
322 | (1) |
|
25.4 Major Types of Sample Extraction Techniques |
|
|
323 | (4) |
|
25.4.1 Liquid-Liquid Extraction |
|
|
323 | (1) |
|
25.4.2 Proteinase K Digestion |
|
|
323 | (2) |
|
25.4.3 Solid-phase Extraction |
|
|
325 | (1) |
|
25.4.4 Ion-exchange Magnetic Bead Extraction |
|
|
325 | (1) |
|
25.4.5 Immunoaffinity Capture Extraction |
|
|
326 | (1) |
|
25.4.6 Preparative Chromatography |
|
|
327 | (1) |
|
25.5 Key Considerations in Sample Preparation for LC-MS Bioanalysis of Oligonucleotides |
|
|
327 | (1) |
|
25.6 Representative Protocols |
|
|
328 | (2) |
|
25.6.1 Quantitation of a Therapeutic Antisense Oligonucleotide from Plasma |
|
|
328 | (1) |
|
25.6.2 Targeted LC-MS of Cellular Messenger RNA |
|
|
329 | (1) |
|
|
330 | (1) |
|
|
330 | (5) |
|
26 Sample Preparation for LC-MS Bioanalysis of Antibody-Drug Conjugates |
|
|
335 | (16) |
|
|
|
|
335 | (1) |
|
26.2 Properties of ADC and Challenges for Sample Preparation |
|
|
335 | (7) |
|
26.2.1 Unconjugated Payload |
|
|
336 | (1) |
|
26.2.2 Conjugated Payload |
|
|
337 | (1) |
|
|
338 | (1) |
|
|
339 | (1) |
|
|
340 | (2) |
|
26.3 Sample Preparation Methods and Common Protocols |
|
|
342 | (5) |
|
26.3.1 Unconjugated Payload |
|
|
342 | (1) |
|
26.3.1.1 Sample Preparation by Protein Precipitation |
|
|
342 | (1) |
|
26.3.1.2 Sample Preparation by SPE |
|
|
342 | (1) |
|
26.3.1.3 Sample Preparation by LLE |
|
|
343 | (1) |
|
26.3.1.4 Sample Preparation by SLE |
|
|
343 | (1) |
|
26.3.1.5 Preparation of Samples with Tissues |
|
|
344 | (1) |
|
26.3.2 Conjugated Payload |
|
|
344 | (1) |
|
26.3.2.1 Sample Preparation Using Anti-idiotype mAb or Anti-human Fc Ab for Immunoaffinity Capture |
|
|
344 | (1) |
|
26.3.2.2 Sample Preparation Using Protein A or Protein G for Capture |
|
|
345 | (1) |
|
26.3.2.3 Sample Preparation for Conjugated Payload Quantification in ADCs with Non-cleavable Linkers |
|
|
346 | (1) |
|
|
346 | (1) |
|
|
346 | (1) |
|
|
347 | (1) |
|
26.3.5.1 Sample Preparation for DAR Analysis on Intact ADC |
|
|
347 | (1) |
|
26.3.5.2 Sample Preparation for DAR Analysis on Reduced ADC |
|
|
347 | (1) |
|
|
347 | (1) |
|
|
348 | (1) |
|
|
348 | (3) |
Index |
|
351 | |